TTX335o / Temple Therap - LARVOL DELTA

Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023 (Businesswire) - "Temple Therapeutics...presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer, and the novel ovarian cell target, lemur tyrosine kinase 3 (LMTK3). The new data was provided at a poster presentation at the American Association of Cancer Research (AACR) Annual Meeting, which took place on April 14-19, 2023 in Orlando....TTX335o specifically targets apoptosis, a major determinant in uncontrolled cell growth in ovarian cancer through a novel integrin (αV/β1), monomeric myeloperoxidase (mMPO), and LMTK3 signaling pathways. Knocking down LMTK3 also induced cell death in ovarian cancer, and more importantly, did not harm normal cells. In vitro and in vivo studies seem to validate LMTK3 as a specific target and predictor of clinical outcomes in ovarian cancer."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor